Research graph
References from Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/0304-4157(86)90002-x
10.1016/0304-4157(86)90002-x · External reference
10.1128/cmr.9.4.512
10.1128/cmr.9.4.512 · External reference
10.1128/aac.28.2.167
10.1128/aac.28.2.167 · External reference
10.1128/aac.27.2.172
10.1128/aac.27.2.172 · External reference
10.1080/02681218780000491
10.1080/02681218780000491 · External reference
Comparative study of both macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards’ proposed standard.
10.1128/jcm.32.10.2494-2500.1994 · 1994 · External reference
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
10.1128/aac.40.3.822 · 1996 · External reference
10.1128/aac.36.2.486
10.1128/aac.36.2.486 · External reference
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp.
10.1128/aac.41.2.233 · 1997 · External reference
10.1111/myc.1990.33.4.203
10.1111/myc.1990.33.4.203 · External reference
New emerging fungal pathogens.
1995 · External reference
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B.
10.1128/jcm.28.7.1616-1622.1990 · 1990 · External reference
10.1002/j.1552-4604.1998.tb04464.x
10.1002/j.1552-4604.1998.tb04464.x · External reference
10.1128/aac.41.6.1275
10.1128/aac.41.6.1275 · External reference
10.1093/infdis/164.2.418
10.1093/infdis/164.2.418 · External reference
10.1128/aac.35.6.1029
10.1128/aac.35.6.1029 · External reference
Serum pharmacology of amphotericin B applied in lipid emulsions.
10.1128/aac.41.4.728 · 1997 · External reference
10.1128/aac.13.2.271
10.1128/aac.13.2.271 · External reference
10.2165/00003088-198308010-00002
10.2165/00003088-198308010-00002 · External reference
10.1093/infdis/152.5.1037
10.1093/infdis/152.5.1037 · External reference
Lipid formulations of amphotericin B: clinical efficacy and toxicities.
10.1086/514704 · 1998 · External reference
10.1093/jac/33.2.203
10.1093/jac/33.2.203 · External reference
10.1016/s0163-4453(94)95941-2
10.1016/s0163-4453(94)95941-2 · External reference
10.1056/nejm199411173312001
10.1056/nejm199411173312001 · External reference
10.1086/514504
10.1086/514504 · External reference
10.1016/0002-9343(91)90006-j
10.1016/0002-9343(91)90006-j · External reference
10.1093/clinids/23.3.556
10.1093/clinids/23.3.556 · External reference
10.1056/nejm199707033370103
10.1056/nejm199707033370103 · External reference
Mucormycosis in the BMT population.
1993 · External reference
10.1016/s0039-6257(05)80041-4
10.1016/s0039-6257(05)80041-4 · External reference
Trichosporon infections: clinical manifestations and treatment.
1993 · External reference
10.1093/clinids/12.2.308
10.1093/clinids/12.2.308 · External reference
10.1093/clinids/20.4.755
10.1093/clinids/20.4.755 · External reference
10.1177/000992289503400704
10.1177/000992289503400704 · External reference
10.1001/archinte.157.14.1589
10.1001/archinte.157.14.1589 · External reference
10.1177/106002809502900512
10.1177/106002809502900512 · External reference
10.1128/aac.36.1.172
10.1128/aac.36.1.172 · External reference
The influence of the duration of infusion on the acute toxicity of amphotericin B.
1991 · External reference
Effect of infusion rate on amphotericin B‐associated febrile reactions.
1988 · External reference
10.1016/0002-9343(92)90040-i
10.1016/0002-9343(92)90040-i · External reference
Unresolved reference
External reference
Amphotericin B revisited: reassessment of toxicity.
1990 · External reference
10.1046/j.1365-2141.1997.2473063.x
10.1046/j.1365-2141.1997.2473063.x · External reference
The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity.
1980 · External reference
10.1128/aac.33.8.1222
10.1128/aac.33.8.1222 · External reference
10.1128/aac.35.12.2509
10.1128/aac.35.12.2509 · External reference
10.1016/s0272-6386(88)80136-7
10.1016/s0272-6386(88)80136-7 · External reference
10.1172/jci115240
10.1172/jci115240 · External reference
10.1016/0002-9343(83)90353-4
10.1016/0002-9343(83)90353-4 · External reference
10.1007/bf01721035
10.1007/bf01721035 · External reference
10.1038/ki.1991.214
10.1038/ki.1991.214 · External reference
Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.
10.1681/asn.v62154 · 1995 · External reference
Sodium chloride treatment of amphotericin B nephrotoxicity.
1995 · External reference
Practical guidelines for preparing and administering amphotericin B.
1992 · External reference
10.1159/000188590
10.1159/000188590 · External reference
10.1007/s005200050224
10.1007/s005200050224 · External reference
10.1007/bf01851836
10.1007/bf01851836 · External reference
Efficacy of low‐dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients.
10.1128/aac.42.12.3103 · 1998 · External reference
10.1093/infdis/158.5.1065
10.1093/infdis/158.5.1065 · External reference
10.1128/aac.38.2.177
10.1128/aac.38.2.177 · External reference
Amphotericin B does not mix with fat emulsion.
10.1093/ajhp/52.13.1463 · 1995 · External reference
10.1093/jac/37.6.1165
10.1093/jac/37.6.1165 · External reference
10.1007/bf01989977
10.1007/bf01989977 · External reference
10.1136/bmj.305.6859.921
10.1136/bmj.305.6859.921 · External reference
10.1093/jac/38.1.117
10.1093/jac/38.1.117 · External reference
10.1016/s0035-9203(96)90272-2
10.1016/s0035-9203(96)90272-2 · External reference
10.1016/0035-9203(94)90236-4
10.1016/0035-9203(94)90236-4 · External reference
10.1097/00003246-199608000-00007
10.1097/00003246-199608000-00007 · External reference
10.1136/bmj.317.7155.379
10.1136/bmj.317.7155.379 · External reference
10.1128/aac.36.2.299
10.1128/aac.36.2.299 · External reference
10.2165/00003088-199223040-00004
10.2165/00003088-199223040-00004 · External reference
10.1016/s0163-4453(94)95971-4
10.1016/s0163-4453(94)95971-4 · External reference
10.1159/000048472
10.1159/000048472 · External reference
Zygomycosis treated with amphotericin B colloidal dispersion. A review of 22 cases.
1996 · External reference
Amphotericin B colloidal dispersion vs.
1997 · External reference
Unresolved reference
External reference
10.1086/514672
10.1086/514672 · External reference
10.1007/bf01575124
10.1007/bf01575124 · External reference
10.1093/infdis/173.5.1208
10.1093/infdis/173.5.1208 · External reference
10.1159/000048469
10.1159/000048469 · External reference
Treatment with high cumulative doses of Amphotericin B colloidal dispersion. Efficacy and tolerance in 96 patients.
1996 · External reference
10.2165/00003495-199856030-00008
10.2165/00003495-199856030-00008 · External reference
10.1073/pnas.85.16.6122
10.1073/pnas.85.16.6122 · External reference
10.1111/j.2042-7158.1991.tb03189.x
10.1111/j.2042-7158.1991.tb03189.x · External reference
10.1128/aac.35.4.615
10.1128/aac.35.4.615 · External reference
Amphotericin B Lipid Complex: review of safety, pharmacokinetics and efficacity.
1996 · External reference
10.1128/aac.42.4.767
10.1128/aac.42.4.767 · External reference
10.1086/516353
10.1086/516353 · External reference
10.1038/sj.bmt.1700664
10.1038/sj.bmt.1700664 · External reference
10.1093/clinids/22.2.315
10.1093/clinids/22.2.315 · External reference
Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience.
10.1111/j.1600-0609.1996.tb01348.x · 1996 · External reference
10.1111/j.1365-2141.1996.tb08988.x
10.1111/j.1365-2141.1996.tb08988.x · External reference
10.1016/s0163-4453(94)95956-0
10.1016/s0163-4453(94)95956-0 · External reference
10.1093/jac/33.5.907
10.1093/jac/33.5.907 · External reference
AmBisome targeting to fungal infections.
1994 · External reference
10.1093/jac/28.suppl_b.49
10.1093/jac/28.suppl_b.49 · External reference
Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation.
10.1111/j.1399-0012.1990.tb00047.x · 1990 · External reference
10.1093/jac/28.suppl_b.73
10.1093/jac/28.suppl_b.73 · External reference
10.1086/515033
10.1086/515033 · External reference
10.1046/j.1365-2141.1998.00944.x
10.1046/j.1365-2141.1998.00944.x · External reference
10.1097/00002030-199712000-00010
10.1097/00002030-199712000-00010 · External reference
10.1056/nejm199903113401004
10.1056/nejm199903113401004 · External reference
10.1097/00007890-199501150-00009
10.1097/00007890-199501150-00009 · External reference
Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients.
1993 · External reference
10.1093/clinids/22.6.938
10.1093/clinids/22.6.938 · External reference
10.1086/515085
10.1086/515085 · External reference
Unresolved reference
External reference
